Glycated Haemoglobin HbA1c
Related Subjects:
|Type 1 DM
|Type 2 DM
|Diabetes in Pregnancy
|HbA1c
|Diabetic Ketoacidosis (DKA) Adults
|Hyperglycaemic Hyperosmolar State (HHS)
|Diabetic Nephropathy
|Diabetic Retinopathy
|Diabetic Neuropathy
🧪 HbA1c reflects average blood glucose control over ~3 months (lifespan of an erythrocyte 🩸).
It provides a long-term marker of glycaemic control compared to daily glucose fluctuations.
ℹ️ About
- 📊 HbA1c reflects integrated blood glucose control over 120 days.
- 🍬 Formed by glucose binding covalently to haemoglobin (HbA beta chain valine).
- 🔄 Sensitive to changes in glycaemic control in the 4 weeks before measurement.
- 📏 Reported in mmol/mol (IFCC). Conversion:
IFCC HbA1c (mmol/mol) = [DCCT HbA1c(%) − 2.15] × 10.929
- ↗️ Rough guide: +11 mmol/mol ≈ +2 mmol/L (36 mg/dL) in mean blood glucose.
🧬 Aetiology
- ⚡ Glycosylation = glucose binds terminal valine of HbA beta chain.
- 📈 Proportional to mean glucose exposure over ~6 weeks.
- 🔹 Fructosamine = glycosylated albumin → reflects control over 2–3 weeks (shorter window).
🎯 Uses
- 🧑⚕️ Guides long-term diabetes management (Type 1 & Type 2).
- 📉 On average, oral hypoglycaemic drugs ↓ HbA1c by ~1%.
- 💊 HbA1c >8% ➝ usually needs pharmacotherapy (not just diet).
HbA1c >9% ➝ consider insulin.
- 👩🍼 In pregnancy ➝ Fructosamine is preferred (shorter half-life, avoids misleading HbA1c).
- ⚠️ Falsely low in haemoglobinopathies (e.g., thalassaemia, sickle cell).
📖 Interpretation
- ✅ Normal population: ~4.5–6.5% (25–48 mmol/mol).
- 🎯 Target in diabetes: 6.5–7.0% (realistically 7.0% for many patients).
- 🏥 Clinical Trials:
- DCCT (Type 1 DM): showed HbA1c links to microvascular complications.
- UKPDS (Type 2 DM): confirmed HbA1c as a marker of microangiopathy risk.
- 📐 Standardisation: IFCC/DCCT alignment avoids inter-lab errors.